Key Highlights
- SELLAS Life Sciences traded at USD 9.25 in pre-market dealings on Friday, November 13, 2026, up 15.19% on pre-market data, with no company announcement dated November 11 to 13 found.
- The Phase 3 REGAL trial reached its prespecified 80th overall survival event on October 28, 2026, which triggered the final analysis, and one published report put the shares fall that day at 18%.
- Preliminary topline results for galinpepimut-S, a WT1-targeting immunotherapy for acute myeloid leukaemia in second remission, are expected this quarter, with no specific date given.
- Cash and equivalents were USD 138.3 million at June 30, 2026, and about 201.95 million shares were outstanding in market data, valuing the stock near USD 1.87 billion at USD 9.25 (calculated).
A Rebound After the Sell-Off Tied to the 80th Event
SELLAS Life Sciences (NASDAQ:SLS) was quoted at USD 9.25 in pre-market dealings on Friday, November 13, 2026, up 15.19% from an implied prior level near USD 8.03 (calculated). No press release, filing or analyst action dated November 11 to 13 was located. On October 28, the company said REGAL had reached its 80th event, which triggers database lock, unblinding and analysis of the primary endpoint, overall survival. The shares fell that day, with published coverage citing an 18% drop in one report and a USD 10.38 close, down 14.71%, in another. Such rebounds can occur without news, and the USD 9.25 quote remains below the USD 10.38 level that followed the milestone news.
What the REGAL Study Tests and When Results Are Due
For SELLAS Life Sciences (NASDAQ:SLS), REGAL is a randomised study intended for registration, testing galinpepimut-S as maintenance treatment in adults with acute myeloid leukaemia in second complete remission, and the product is licensed from Memorial Sloan Kettering Cancer Center. Because the study is event-driven, the 80th death set the timing of the analysis. The company plans to announce preliminary topline results this quarter, which means by December 31, 2026 (calculated). It has also said it will present SLS009 combination data in high-risk AML at the 2026 American Society of Hematology meeting, with a December 14 date drawn from published coverage. SLS009 is a CDK9 inhibitor, so the stock reflects two programmes, with galinpepimut-S carrying most of the near-term weight.
Binary Readout Risk, Cash Runway and Possible Financing
SELLAS Life Sciences faces a readout that can move the valuation sharply, and the October fall showed holders did not treat the milestone as a certain win. Cash of USD 138.3 million at June 30 compares with a net loss of about USD 32.5 million in market data, though the period for that loss is unclear, so the funding runway is not determinable. Favourable results might trigger a fundraising, while poor results could jeopardise the programme. The 52-week range is USD 1.39 to USD 15.88, and pre-market moves can reverse. Recent coverage put the year-to-date gain at about 128% as of November 10, which means expectations are already high ahead of the readout.
Where Things Stand
No identifiable news explains the 15.19% pre-market gain in SELLAS Life Sciences (NASDAQ:SLS), which looks like a rebound after the October 28 sell-off and positioning ahead of the REGAL readout. The USD 9.25 quote is pre-market only. The evidence is balanced: the milestone has been hit, yet the outcome remains unknown. Track the topline release due this quarter, the December SLS009 presentation, the third-quarter report and any funding that follows the data.
_11_17_2026_06_50_14_402066.jpg)





Please wait processing your request...